Revenue grew significantly year-over-year, driven by strong pharmacy performance and geographic expansion, while net losses narrowed slightly.

The Oncology Institute delivered a strong second quarter in 2025, with consolidated revenue increasing by 21.5% year-over-year to $119.8 million. This growth was primarily fueled by exceptional performance in the pharmacy business, which saw over 40% year-over-year growth, and the addition of over 50,000 new capitated lives. The company also significantly reduced its Adjusted EBITDA loss by 53.1% compared to the prior year, demonstrating improved operational efficiency.

The Oncology Institute generated $104.4 million in revenue in Q1 2025, driven by strong performance in its dispensary segment and moderate growth in patient services. The company narrowed its net loss to $19.6 million, achieved a 44.1% increase in gross profit, and significantly improved its adjusted EBITDA. Strategic capitation contracts added over 100,000 covered lives and supported guidance reaffirmation.

The Oncology Institute achieved $100 million in revenue for Q4 2024, representing a 16.9% year-over-year increase. Dispensary revenue saw significant growth, while patient services declined due to the loss of a major contract. The company reported a net loss of $13.2 million for the quarter and continues to improve operational efficiency and cash flow.

The Oncology Institute announced a successful Q3 2024, marked by significant revenue growth and increased profitability. The company's strategic focus on expanding its therapeutic offerings and strengthening partnerships has yielded positive results, positioning it for continued success.

The Oncology Institute announced strong financial results for Q2 2024, marked by a significant increase in revenue and EPS. The company's growth was fueled by expanded patient services and successful strategic partnerships, positioning it for continued success in the oncology market.

The Oncology Institute (TOI) reported a 24.2% increase in consolidated revenue, reaching $95 million for Q1 2024. The company signed seven new capitation and value-based contracts across three states. Despite revenue growth, gross profit decreased by 15.1% year-over-year to $12 million. Net loss improved to $19.9 million compared to $30.0 million in the prior year quarter. The company reaffirms its full year 2024 guidance.

The Oncology Institute is positioned for substantial growth, focusing on its value-based care model within the expanding oncology market. The company's model aims to improve care quality and reduce costs. TOI's revenue growth is demonstrated by its increase in value-based members and expansion into new markets.

The Oncology Institute reported a 26% increase in consolidated revenue, reaching $82 million for Q3 2023. Gross profit increased by 23% to $16 million, while the company experienced a net loss of $17.4 million. The company reaffirmed its full year 2023 guidance.

The Oncology Institute announced positive Q2 2023 results, demonstrating revenue growth and solid financial performance. Key strategic initiatives contributed to the company's success during the quarter.

The Oncology Institute (TOI) reported a strong start to 2023 with a 38.1% increase in consolidated revenue, reaching $76 million. However, the company experienced a net loss of $30.0 million, a significant decrease compared to the prior year's net income of $19.3 million, primarily due to a decrease in the change in fair value of earnout liabilities and a goodwill impairment charge.

The Oncology Institute (TOI) reported a 36.6% increase in consolidated revenue, reaching $71 million for Q4 2022. Gross profit increased by 87.6% to $16 million. The company ended the year with $132 million in cash, cash equivalents, and investments.

The Oncology Institute's investor presentation highlighted their position as a leading value-based oncology care platform, emphasizing their disruptive model, growth opportunities, and financial overview, including a revenue guidance of $245 to $250 million for 2022.

The Oncology Institute (TOI) anticipates revenue between $270 to $310 million, representing approximately 33% to 53% growth over 2021 revenue. Gross Profit is expected to be $50 to $60 million and adjusted EBITDA is expected to be between $(20) to $(25) million. TOI anticipates 1.75 million to 2.0 million lives at year end, representing approximately 9% to 25% growth over year-end 2021 lives.

The Oncology Institute (TOI) reported a strong first quarter in 2022 with a 13.5% increase in revenue compared to Q1 2021, reaching $55 million. The company also saw a rise in gross profit and net income, driven by new partnerships and cost management improvements.